Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022
Fore Biotherapeutics, a precision oncology company developing treatments for patients with genetically defined cancers whose current treatment options are limited, today announced that data from the
France General Kostenloser Wertpapierhandel Ericj Sherman European Society Of Medical Oncology Congress Memorial Sloan Kettering Cancer Center Developmental Therapeutics
Source: finanznachrichten.de